Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

Bellicum Pharmaceuticals logo

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Advanced Chart

Key Stats

Today's Range
$0.07
$0.09
50-Day Range
$0.07
$0.10
52-Week Range
$0.06
$1.31
Volume
6,059 shs
Average Volume
22,874 shs
Market Capitalization
$726.57 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Stock News Headlines

Bellicum Pharmaceuticals Inc (BLCM)
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Bellicum Pharmaceuticals Inc BLCM
Futura Medical plc (FAMDF)
See More Headlines

BLCM Stock Analysis - Frequently Asked Questions

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company had revenue of $0.70 million for the quarter.

Shares of Bellicum Pharmaceuticals reverse split on Thursday, February 6th 2020.The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Bellicum Pharmaceuticals (BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), NVIDIA (NVDA), CyberArk Software (CYBR), Gilead Sciences (GILD) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
8/11/2021
Today
7/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.97 million
Pretax Margin
-1,492.40%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
0.33

Miscellaneous

Free Float
8,716,000
Market Cap
$726.57 thousand
Optionable
Not Optionable
Beta
1.39

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:BLCM) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners